Zacks Research Issues Positive Forecast for CRL Earnings

Key Points

• Zacks Research has increased their Q3 2025 earnings per share estimate for Charles River Laboratories from $2.31 to $2.32, contributing to a current consensus estimate of $9.36 for the full year.
• Following a strong quarterly earnings report, Charles River Laboratories saw a range of rating upgrades from various analysts, with an average consensus price target of $179.93.
• The company's stock has recently experienced institutional inflows, with institutional investors owning approximately 98.91% of the company's stock.

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Investment analysts at Zacks Research boosted their Q3 2025 earnings per share estimates for shares of Charles River Laboratories International in a report released on Monday, October 13th. Zacks Research analyst Team now expects that the medical research company will post earnings per share of $2.32 for the quarter, up from their prior estimate of $2.31. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International's FY2025 earnings at $10.12 EPS, Q4 2026 earnings at $2.65 EPS and Q3 2027 earnings at $2.72 EPS.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.50 by $0.62. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.Charles River Laboratories International's revenue for the quarter was up .6% on a year-over-year basis. During the same period last year, the company earned $2.80 EPS.

Several other research analysts also recently weighed in on CRL. William Blair upgraded shares of Charles River Laboratories International from a "market perform" rating to an "outperform" rating in a research report on Monday, October 6th. Weiss Ratings restated a "sell (d)" rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. Evercore ISI lifted their target price on Charles River Laboratories International from $190.00 to $200.00 and gave the company an "outperform" rating in a research report on Friday, October 3rd. Wall Street Zen upgraded Charles River Laboratories International from a "buy" rating to a "strong-buy" rating in a research report on Wednesday. Finally, Citigroup raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $150.00 to $200.00 in a research report on Wednesday, July 9th. Eight investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $179.93.

Charles River Laboratories International Stock Down 0.3%

Shares of Charles River Laboratories International stock opened at $170.05 on Wednesday. Charles River Laboratories International has a twelve month low of $91.86 and a twelve month high of $230.02. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The company's 50 day moving average is $159.35 and its 200 day moving average is $147.74. The company has a market cap of $8.37 billion, a price-to-earnings ratio of -127.86, a price-to-earnings-growth ratio of 4.56 and a beta of 1.50.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Brooklyn Investment Group raised its position in Charles River Laboratories International by 93.5% during the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock valued at $27,000 after purchasing an additional 86 shares during the period. Cromwell Holdings LLC raised its stake in shares of Charles River Laboratories International by 542.9% in the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company's stock valued at $27,000 after acquiring an additional 152 shares during the period. Neo Ivy Capital Management bought a new stake in shares of Charles River Laboratories International in the 2nd quarter worth about $29,000. HM Payson & Co. bought a new position in Charles River Laboratories International during the 1st quarter valued at about $31,000. Finally, Geneos Wealth Management Inc. grew its stake in shares of Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company's stock valued at $44,000 after buying an additional 145 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 800 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the sale, the executive vice president owned 24,116 shares in the company, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.